Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Target therapies for radioiodine refractory advanced thyroid tumors.

Schlumberger M.

J Endocrinol Invest. 2012;35(6 Suppl):40-4. Review.

PMID:
23014073
2.

New perspectives on the treatment of differentiated thyroid cancer.

Coelho SM, Carvalho DP, Vaisman M.

Arq Bras Endocrinol Metabol. 2007 Jun;51(4):612-24. Review.

3.

Update on thyroid cancer treatment.

Regalbuto C, Frasca F, Pellegriti G, Malandrino P, Marturano I, Di Carlo I, Pezzino V.

Future Oncol. 2012 Oct;8(10):1331-48. doi: 10.2217/fon.12.123. Review.

PMID:
23130931
4.

Radioiodine therapy of metastatic lesions of differentiated thyroid cancer.

Luster M, Hänscheid H, Freudenberg LS, Verburg FA.

J Endocrinol Invest. 2012;35(6 Suppl):21-9. Review.

PMID:
23014070
5.

Targeted therapy in radioiodine refractory thyroid cancer.

Pacini F, Brilli L, Marchisotta S.

Q J Nucl Med Mol Imaging. 2009 Oct;53(5):520-5. Review.

6.

Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer.

Kim WG, Kim EY, Kim TY, Ryu JS, Hong SJ, Kim WB, Shong YK.

Endocr J. 2009;56(1):105-12.

7.

Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.

Liu YY, van der Pluijm G, Karperien M, Stokkel MP, Pereira AM, Morreau J, Kievit J, Romijn JA, Smit JW.

Clin Endocrinol (Oxf). 2006 Jun;64(6):617-24.

PMID:
16712662
8.

Molecular targeted therapies for patients with refractory thyroid cancer.

Chougnet C, Brassard M, Leboulleux S, Baudin E, Schlumberger M.

Clin Oncol (R Coll Radiol). 2010 Aug;22(6):448-55. doi: 10.1016/j.clon.2010.04.008. Review.

PMID:
20554167
9.

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC 3rd, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C; Endocrine Malignancies Disease Oriented Group.; Mayo Clinic Cancer Center.; Mayo Phase 2 Consortium..

Lancet Oncol. 2010 Oct;11(10):962-72. doi: 10.1016/S1470-2045(10)70203-5.

10.

Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets.

Spitzweg C, Bible KC, Hofbauer LC, Morris JC.

Lancet Diabetes Endocrinol. 2014 Oct;2(10):830-42. doi: 10.1016/S2213-8587(14)70051-8. Review.

PMID:
24898835
11.

The current role of targeted therapies to induce radioiodine uptake in thyroid cancer.

Fröhlich E, Wahl R.

Cancer Treat Rev. 2014 Jun;40(5):665-74. doi: 10.1016/j.ctrv.2014.01.002. Review.

PMID:
24485648
12.

Radioiodine therapy for thyroid cancer in the era of risk stratification and alternative targeted therapies.

Pryma DA, Mandel SJ.

J Nucl Med. 2014 Sep;55(9):1485-91. doi: 10.2967/jnumed.113.131508. Review.

13.

"High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.

Menzel C, Grünwald F, Schomburg A, Palmedo H, Bender H, Späth G, Biersack HJ.

J Nucl Med. 1996 Sep;37(9):1496-503.

14.

New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era.

Capdevila J, Argiles G, Rodriguez-Frexinos V, Nuñez I, Tabernero J.

Discov Med. 2010 Feb;9(45):153-62. Review.

15.

[Advances in the treatment of thyroid cancer in the era of molecularly targeted therapies].

Malouf G, Baudin E, Soria JC, Schlumberger M.

Bull Cancer. 2009 Jan;96(1):95-101. doi: 10.1684/bdc.2008.0798. Review. French.

16.

Redifferentiating agents in non-radioiodine avid cancer.

Seregni E, Vellani C, Castellani MR, Maccauro M, Pallotti F, Scaramellini G, Guzzo M, Greco A.

Q J Nucl Med Mol Imaging. 2009 Oct;53(5):513-9. Review.

17.

New molecular targeted therapies in thyroid cancer.

Milano A, Chiofalo MG, Basile M, Salzano de Luna A, Pezzullo L, Caponigro F.

Anticancer Drugs. 2006 Sep;17(8):869-79. Review.

PMID:
16940797
18.

Radioiodine post-surgical remnant ablation in patients with differentiated thyroid cancer: news from the last 10 years.

Molinaro E, Pieruzzi L, Viola D.

J Endocrinol Invest. 2012;35(6 Suppl):16-20. Review.

PMID:
23014069
19.

New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.

Wang E, Karedan T, Perez CA.

Anticancer Drugs. 2015 Aug;26(7):689-97. doi: 10.1097/CAD.0000000000000247. Review.

PMID:
25974026
20.

Targeted treatments of radio-iodine refractory differentiated thyroid cancer.

de la Fouchardière C.

Ann Endocrinol (Paris). 2015 Feb;76(1 Suppl 1):1S34-9. doi: 10.1016/S0003-4266(16)30012-9. Review.

PMID:
26826481
Items per page

Supplemental Content

Support Center